
Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.




























